阿帕替尼联合希罗达治疗晚期胃癌的临床疗效观察

Clinical Effect Observation of Apatinib Combined Xeloda for Patients with Advanced Gastric Cancer

摘要: 目的：探讨甲磺酸阿帕替尼靶向治疗联合希罗达口服化疗在晚期胃癌治疗临床作用。方法：将60例晚期二线化疗或二线化疗失败的胃癌随机分为两组，研究组30例，使用甲磺酸阿帕替尼联合希罗达，对照组30例，采用单药希罗达口服化疗方案。结果：入组病例均可进行有价值的临床疗效评价。研究组完全缓解率(CR) 0%，部分缓解率(PR8例) 26.7%，稳定(SD10例) 40.0%，疾病控制率(DCR)，66.7%，对照组完全缓解率(CR) 0%，部分缓解率(PR2例) 13.3%，稳定2例，疾病控制率(DCR) 26.6%，研究组有效率高于对照组，两组间比较，差异有统计学意义(P < 0.05)。不良反应：两组口腔炎、手足综合征方面有统计学意义(P < 0.05)，而在白细胞减少、贫血、血小板减少、腹泻、恶心呕吐、肝功能异常方面、周围神经损伤两组比较差异无统计学意义(P > 0.05)。结论：探讨甲磺酸阿帕替尼联合希罗达在晚期胃癌化疗中仍有较好的疾病控制，不良反应较少可控，有较好的临床价值。

Abstract: Objective: To investigate the efficacy and safety ofapatinib combined xeloda for patients with advanced gastric cancer. Method: 60 patients with advanced gastric cancer were randomly divided into two groups. The treatment group was administrated with apatinib combined xeloda; The control group was administrated with single xeloda. Result: The Disease control rate (DCR) was 66.7%, with 0 cases (0%) CR, 26.7% PR, 40.0% SD, in thetreatment group, and the Disease control rate (DCR) was 26.6%, with 0 cases (0%) CR, 13.3% PR, 13.3% SD, in control group. Results: There was statistically significant difference between the treatment group and the control group in Disease control rate (66.7% versus 26.6%) (P < 0.05). Adverse Reaction: There were significant differences in stomatitis, hand and foot syndrome between the two groups (P < 0.05), but in leu-kopenia, anemia, thrombocytopenia, diarrhea, nausea and vomiting, abnormal liver function, pe-ripheral nerve injury. There was no significant difference in between the two groups (P > 0.05). Conclusion: Apatinib combined with Xeloda still has better disease control, less adverse reactions and better clinical value in advanced gastric cancer chemotherapy.